Skip to main content

Published locations for VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits

User login

  • Reset your password
  • /content/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i-benefits
  • /internalmedicinenews/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms
  • /clinicalendocrinologynews/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial
  • /ecardiologynews/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i
  • /cardiology/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i
  • /endocrinology/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i
  • /internalmedicine/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i
  • /type-2-diabetes-icymi/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms